Literature DB >> 22748649

Immunotherapy for glioma: promises and challenges.

Seunggu J Han1, Corinna Zygourakis, Michael Lim, Andrew T Parsa.   

Abstract

Novel immunotherapeutic modalities are being pursed in the treatment of high-grade gliomas. This article explains how tumors suppress immune function in the brain. It specifically describes the ways in which tumors limit effective communication with immune cells, secrete immune-inhibitory cytokines and molecules, and express molecules that induce apoptosis of immune cells. It also defines 3 different immunotherapeutic approaches to counteract this tumor-associated immunosuppression: cytokine therapy, passive immunotherapy (either serotherapy or adoptive immunotherapy), and active immunotherapy. Although immunotherapeutic approaches have met with mixed success so far, immunotherapy continues to be actively pursued because of its potential to attack infiltrating high-grade gliomas.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22748649     DOI: 10.1016/j.nec.2012.05.001

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN: 1042-3680            Impact factor:   2.509


  11 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.

Authors:  Guanzhang Li; Zheng Wang; Chuanbao Zhang; Xing Liu; Jinquan Cai; Zhiliang Wang; Huimin Hu; Fan Wu; Zhaoshi Bao; Yanwei Liu; Liang Zhao; Tingyu Liang; Fan Yang; Ruoyu Huang; Wei Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2017-07-28       Impact factor: 8.110

3.  Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging.

Authors:  Liang Han; Derek K Kong; Ming-Qiang Zheng; Sasidhar Murikinati; Chao Ma; Peng Yuan; Liyuan Li; Daofeng Tian; Qiang Cai; Chunlin Ye; Daniel Holden; June-Hee Park; Xiaobin Gao; Jean-Leon Thomas; Jaime Grutzendler; Richard E Carson; Yiyun Huang; Joseph M Piepmeier; Jiangbing Zhou
Journal:  ACS Nano       Date:  2016-03-16       Impact factor: 15.881

4.  Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.

Authors:  Vaidehi Mahadev; Renate Starr; Sarah L Wright; Catalina Martinez; Michael C Jensen; Michael E Barish; Stephen J Forman; Christine E Brown
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 5.  A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.

Authors:  Dong-Sup Chung; Hye-Jin Shin; Yong-Kil Hong
Journal:  J Immunol Res       Date:  2014-06-09       Impact factor: 4.818

6.  LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas.

Authors:  Jun Su; Qianquan Ma; Wenyong Long; Hailin Tang; Changwu Wu; Mei Luo; Xiangyu Wang; Kai Xiao; Yang Li; Qun Xiao; Chi Zhang; Haoyu Li; Qing Liu
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

7.  The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis.

Authors:  Amina Ghouzlani; Soumaya Rafii; Mehdi Karkouri; Abdelhakim Lakhdar; Abdallah Badou
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

8.  Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.

Authors:  Maria Teresa Solomón; Julio César Selva; Javier Figueredo; José Vaquer; Carolina Toledo; Nelson Quintanal; Silvia Salva; Rafael Domíngez; José Alert; Jorge Juan Marinello; Mauricio Catalá; Martha González Griego; Juan Antonio Martell; Patricia Lorenzo Luaces; Javier Ballesteros; Niurys de-Castro; Ferdinand Bach; Tania Crombet
Journal:  BMC Cancer       Date:  2013-06-19       Impact factor: 4.430

Review 9.  Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I).

Authors:  Alice Giotta Lucifero; Sabino Luzzi
Journal:  Brain Sci       Date:  2021-03-18

10.  The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.

Authors:  Amina Ghouzlani; Abdelhakim Lakhdar; Soumaya Rafii; Mehdi Karkouri; Abdallah Badou
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.